Abstract 2267P
Background
Observational studies have suggested an association between coronary heart disease and increased risk of lung cancer, but the causal relationship between these two conditions remains uncertain. Therefore, we conducted a two-sample Mendelian randomization study to investigate whether there is a causal relationship between coronary heart disease and higher risk of lung cancer.
Methods
We utilized 37 single nucleotide polymorphisms (SNPs) associated with coronary heart disease (with a p-value <5x10-8) from a genome-wide association study involving 184,305 European individuals in the CARDIoGRAMplusC4D Consortium as instrumental variables. Summary data for lung cancer were obtained from the International Lung Cancer Consortium, including 11,348 cases and 15,861 controls. We conducted primary MR analysis using the inverse-variance weighted method and evaluated the MR assumptions in sensitivity analyses. Subgroup analyses were performed for different histological subtypes of lung cancer, and all analyses were carried out using the TwoSampleMR package in R.
Results
The MR analysis revealed that a genetic predisposition to coronary heart disease had a protective effect against the development of lung cancer, with an odds ratio (OR) of 0.88 (95% confidence interval [CI] 0.78-0.99, P=0.035). Subgroup analyses indicated a decreased risk for squamous cell lung cancer (OR 0.80, 95% CI 0.68-0.93, P=0.004), but no significant association was observed in lung adenocarcinoma (OR = 0.87; 95% CI 0.73-1.03, P=0.106). Sensitivity analyses supported a causal interpretation of the findings, indicating that major bias from genetic pleiotropy was unlikely.
Conclusions
Contrary to findings from previous observational studies, our results suggest that coronary heart disease may have a protective effect against the development of lung cancer. These findings emphasize the need to further investigate the underlying mechanisms linking these two conditions and provide a foundation for future research in this field.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Caichen Li.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262P - Baseline-informed versus tumor-agnostic minimal residual disease (MRD) concordance study in patients with HER2+ gastroesophageal adenocarcinoma patients
Presenter: Pan Du
Session: Poster session 08
2263P - Ethnicity-specific distribution of BRCA1, BRCA2, PALB2 and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus
Presenter: Evgeny Imyanitov
Session: Poster session 08
2264P - Proteomics-based phenotypic classification of non-smallcell lung cancer
Presenter: Olena Berkovska
Session: Poster session 08
2265P - miR-4487 enhances gefitinib-mediated ubiquitination and autophagic degradation of EGFR in non-small cell lung cancer cells by targeting USP37
Presenter: Sei-Hoon Yang
Session: Poster session 08
2266P - IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort
Presenter: Marie Morfouace
Session: Poster session 08
2269P - Patient derived xenografts generated from circulating cancer stem cells on chorioallantoic membrane as an alternative pre-clinical model for personalized medicine in pancreatic cancer
Presenter: Monika Pizon
Session: Poster session 08
2270P - Integrative analyses of bulk and single-cell RNA-seq identified diabetes mellitus-related signature as a prognostic factor in pancreatic adenocarcinoma
Presenter: Le Tang
Session: Poster session 08
2271P - Development of an oncolytic virus for the treatment of high grade serous ovarian cancer and other stromal rich tumours
Presenter: Miriam Bazan Peregrino
Session: Poster session 08
2272P - Minimal DNA-methylation (DNAm) signatures for non-invasive tumor-agnostic estimation of tumor content (TC) and molecular subtype in patients (pts) with metastatic breast cancer (mBC)
Presenter: Matteo Benelli
Session: Poster session 08
2273P - Influence of body mass index (BMI) on the response to chemotherapy in patients with HER2+ breast cancer: Role of the leptin axis
Presenter: Marta González Rodríguez
Session: Poster session 08